Brief: Enlivex Announces Reprioritization Plan And Second Quarter 2023 Financial Results
11/09/2023 13:51
Sept 11 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES REPRIORITIZATION PLAN AND SECOND QUARTER
2023
FINANCIAL RESULTS
* ENLIVEX THERAPEUTICS LTD- AS PART OF STRATEGIC
REPRIORITIZATION
PLAN, COMPANY HAS INITIATED A CLINICAL PROGRAM IN OSTEOARTHRITIS
* ENLIVEX THERAPEUTICS LTD- COMPANY INTENDS TO REDUCE ITS
WORKFORCE BY APPROXIMATELY 50%
* ENLIVEX THERAPEUTICS LTD- WORKFORCE REDUCTIONS ARE
EXPECTED TO
RESULT IN A SUBSTANTIAL EXTENSION OF COMPANY'S CASH RUNWAY
THROUGH END OF 2025
* ENLIVEX THERAPEUTICS- CO'S REVISED STRATEGY IS TARGETED AT
OBTAINING TOPLINE DATA READOUTS FROM TWO ADVANCED-STAGE CLINICAL
INDICATIONS BY MID-2025
Source text for Eikon: ID:nGNXbS2cbV
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment